ATE243511T1 - Verwendung von d-methionin zur verminderung der toxizität von ototoxischen arzneimitteln und geräusch - Google Patents
Verwendung von d-methionin zur verminderung der toxizität von ototoxischen arzneimitteln und geräuschInfo
- Publication number
- ATE243511T1 ATE243511T1 AT98915362T AT98915362T ATE243511T1 AT E243511 T1 ATE243511 T1 AT E243511T1 AT 98915362 T AT98915362 T AT 98915362T AT 98915362 T AT98915362 T AT 98915362T AT E243511 T1 ATE243511 T1 AT E243511T1
- Authority
- AT
- Austria
- Prior art keywords
- noise
- methionine
- methods
- platinum
- radiation
- Prior art date
Links
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 231100000199 ototoxic Toxicity 0.000 title 1
- 230000002970 ototoxic effect Effects 0.000 title 1
- 231100000419 toxicity Toxicity 0.000 title 1
- 230000001988 toxicity Effects 0.000 title 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 abstract 2
- 239000002171 loop diuretic Substances 0.000 abstract 2
- 229910052697 platinum Inorganic materials 0.000 abstract 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 abstract 2
- 230000005855 radiation Effects 0.000 abstract 2
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 235000001258 Cinchona calisaya Nutrition 0.000 abstract 1
- 229930182818 D-methionine Natural products 0.000 abstract 1
- 206010063602 Exposure to noise Diseases 0.000 abstract 1
- 206010073306 Exposure to radiation Diseases 0.000 abstract 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 206010029350 Neurotoxicity Diseases 0.000 abstract 1
- 206010044221 Toxic encephalopathy Diseases 0.000 abstract 1
- 231100000360 alopecia Toxicity 0.000 abstract 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 abstract 1
- 239000000797 iron chelating agent Substances 0.000 abstract 1
- 229940075525 iron chelating agent Drugs 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 231100000228 neurotoxicity Toxicity 0.000 abstract 1
- 230000007135 neurotoxicity Effects 0.000 abstract 1
- 239000003223 protective agent Substances 0.000 abstract 1
- 229960001404 quinidine Drugs 0.000 abstract 1
- 229960000948 quinine Drugs 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
- 208000016261 weight loss Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/942,845 US6187817B1 (en) | 1996-10-03 | 1997-10-02 | Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds |
| PCT/US1998/006960 WO1999017765A1 (en) | 1997-10-02 | 1998-04-08 | Use of d-methionine to reduce the toxicity of ototoxic drugs, noise, and radiation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE243511T1 true ATE243511T1 (de) | 2003-07-15 |
Family
ID=25478684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98915362T ATE243511T1 (de) | 1997-10-02 | 1998-04-08 | Verwendung von d-methionin zur verminderung der toxizität von ototoxischen arzneimitteln und geräusch |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6187817B1 (de) |
| EP (1) | EP1019036B1 (de) |
| JP (1) | JP2001518499A (de) |
| AT (1) | ATE243511T1 (de) |
| AU (1) | AU753039B2 (de) |
| CA (1) | CA2303901C (de) |
| DE (1) | DE69815872T2 (de) |
| ES (1) | ES2202834T3 (de) |
| PT (1) | PT1019036E (de) |
| WO (1) | WO1999017765A1 (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6187817B1 (en) * | 1996-10-03 | 2001-02-13 | Southern Illinois University School Of Medicine | Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds |
| US7071230B2 (en) * | 1997-10-02 | 2006-07-04 | Board Of Trustees Of Southern Illinois University | Therapeutic use of D-methionine to reduce the toxicity of noise |
| TW465235B (en) | 1998-09-17 | 2001-11-21 | United Video Properties Inc | Electronic program guide with digital storage |
| US20040082509A1 (en) * | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| WO2004096256A1 (en) * | 2001-01-23 | 2004-11-11 | The United States Of America, As Represented By The Secretary Of The Navy | Methods for preventing and treating loss of balance function due to oxidative stress |
| PL370867A1 (en) * | 2001-09-24 | 2005-05-30 | Tosk, Inc. | Reduced toxicity cisplatin formulations and methods for using the same |
| US7700134B2 (en) * | 2002-01-17 | 2010-04-20 | The Regents Of The University Of Michigan | Prevention of cisplatin induced deafness |
| AU2003299560A1 (en) * | 2002-11-13 | 2004-06-03 | Sepracor, Inc. | Compositions and methods for treating or preventing hearing impairment |
| US20050090551A1 (en) * | 2003-10-27 | 2005-04-28 | Board Of Trustees Of Southern Illinois University | Therapeutic use of methionine for the treatment or prevention of mucositis |
| CA2581076A1 (en) * | 2004-09-14 | 2006-03-23 | Molecular Therapeutics, Inc. | D-methionine formulation with improved biopharmaceutical properties |
| EP1886112B1 (de) | 2005-04-06 | 2014-07-09 | Washington University St. Louis | Verfahren zur messung des metabolismus natürlich abgeleiteter biomoleküle in vivo |
| WO2007031098A1 (en) * | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| JP2009510077A (ja) * | 2005-09-29 | 2009-03-12 | ネクター セラピューティックス | 抗生物質製剤、単位用量、キットおよび方法 |
| WO2007044700A2 (en) * | 2005-10-07 | 2007-04-19 | Board Of Trustees Of Southern Illinois University | Protectant combinations for reducing toxicities |
| USRE46372E1 (en) | 2006-01-19 | 2017-04-25 | The Regents Of The Univerity Of Michigan | Method for treating hearing loss |
| US9770433B2 (en) | 2006-01-19 | 2017-09-26 | The Regents Of The University Of Michigan | Composition and method for treating tinnitus |
| US8927528B2 (en) | 2006-01-19 | 2015-01-06 | The Regents Of The University Of Michigan | Composition for treating hearing loss |
| US20090155390A1 (en) * | 2006-01-19 | 2009-06-18 | Miller Josef M | Composition and method of treating temporary and permanent hearing loss |
| US10238599B2 (en) | 2006-01-19 | 2019-03-26 | The Regents Of The University Of Michigan | Composition and method for treating congenital cytomegalovirus induced hearing loss |
| US9889156B2 (en) | 2006-01-19 | 2018-02-13 | The Regents Of The University Of Michigan | Method for treating noise-induced hearing loss (NIHL) |
| US9919008B2 (en) | 2006-01-19 | 2018-03-20 | The Regents Of The University Of Michigan | Method for treating age-related hearing loss (ARHL) |
| US7951845B2 (en) * | 2006-01-19 | 2011-05-31 | The Regents Of The University Of Michigan | Composition and method of treating hearing loss |
| US8338397B2 (en) | 2006-01-19 | 2012-12-25 | The Regents Of The University Of Michigan | Composition and method of treating side effects from antibiotic treatment |
| WO2007112433A2 (en) * | 2006-03-28 | 2007-10-04 | Novus International Inc. | Compositions for promoting hair growth |
| US20090111736A1 (en) * | 2007-10-29 | 2009-04-30 | Sri International | Orally-Absorbed Solid Dose Formulation for Vancomycin |
| WO2009143864A1 (en) * | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
| WO2009143865A1 (en) * | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| JP5457813B2 (ja) * | 2009-12-16 | 2014-04-02 | ルネサスエレクトロニクス株式会社 | Ａｄｐｌｌ回路、半導体装置及び携帯情報機器 |
| WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
| WO2012048721A1 (en) | 2010-10-14 | 2012-04-19 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
| WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
| HK1209040A1 (en) * | 2012-05-30 | 2016-03-24 | Sensorion | Methods for treating vestibulotoxicity |
| WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| AU2014301631A1 (en) | 2013-06-26 | 2015-08-27 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
| WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| CA2962969C (en) | 2014-09-30 | 2023-03-21 | Washington University | Tau kinetic measurements |
| JP2023524824A (ja) * | 2020-05-06 | 2023-06-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｋｅｌｃｈドメイン含有７Ｂ（ＫＬＨＤＣ７Ｂ）バリアント及びその使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2732400A (en) | 1956-01-24 | Method of preparing methionine | ||
| US4426372A (en) | 1980-08-08 | 1984-01-17 | Regents Of The University Of Minnesota | Inhibition of undesired effects of platinum(II) compounds |
| US5002755A (en) | 1988-02-18 | 1991-03-26 | Vanderbilt University | Method of controlling nephrotoxicity of anti-tumor plaintum compounds |
| US5292773A (en) | 1990-02-14 | 1994-03-08 | Hirsch Gerald P | Treating aids and HIV infection with methionine |
| JPH06192109A (ja) | 1992-09-04 | 1994-07-12 | Fuji Kagaku Kogyo Kk | 抗腫瘍効果増強剤 |
| US6187817B1 (en) * | 1996-10-03 | 2001-02-13 | Southern Illinois University School Of Medicine | Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds |
-
1997
- 1997-10-02 US US08/942,845 patent/US6187817B1/en not_active Expired - Lifetime
-
1998
- 1998-04-08 US US09/057,065 patent/US6265386B1/en not_active Expired - Lifetime
- 1998-04-08 DE DE69815872T patent/DE69815872T2/de not_active Expired - Lifetime
- 1998-04-08 AT AT98915362T patent/ATE243511T1/de not_active IP Right Cessation
- 1998-04-08 ES ES98915362T patent/ES2202834T3/es not_active Expired - Lifetime
- 1998-04-08 EP EP98915362A patent/EP1019036B1/de not_active Expired - Lifetime
- 1998-04-08 CA CA002303901A patent/CA2303901C/en not_active Expired - Fee Related
- 1998-04-08 PT PT98915362T patent/PT1019036E/pt unknown
- 1998-04-08 JP JP2000514636A patent/JP2001518499A/ja active Pending
- 1998-04-08 WO PCT/US1998/006960 patent/WO1999017765A1/en not_active Ceased
- 1998-04-08 AU AU69568/98A patent/AU753039B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ES2202834T3 (es) | 2004-04-01 |
| DE69815872T2 (de) | 2004-07-08 |
| DE69815872D1 (de) | 2003-07-31 |
| JP2001518499A (ja) | 2001-10-16 |
| WO1999017765A1 (en) | 1999-04-15 |
| PT1019036E (pt) | 2003-11-28 |
| EP1019036B1 (de) | 2003-06-25 |
| US6187817B1 (en) | 2001-02-13 |
| EP1019036A1 (de) | 2000-07-19 |
| AU6956898A (en) | 1999-04-27 |
| US6265386B1 (en) | 2001-07-24 |
| CA2303901A1 (en) | 1999-04-15 |
| CA2303901C (en) | 2008-09-09 |
| AU753039B2 (en) | 2002-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE243511T1 (de) | Verwendung von d-methionin zur verminderung der toxizität von ototoxischen arzneimitteln und geräusch | |
| Sheth et al. | Mechanisms of cisplatin-induced ototoxicity and otoprotection | |
| EP1478406A4 (de) | Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung | |
| CA2294247A1 (en) | Antioxidant enhancement of therapy for hyperproliferative conditions | |
| EE03523B1 (et) | Fenantridiinid, neid sisaldavad ravimid ja nende kasutamine | |
| ATE276764T1 (de) | Camptothecin arzneimittelkombinationen mit verringerten nebenwirkungen | |
| IL256054A (en) | A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders | |
| TR199901904T2 (xx) | 3-piridil enantiyomerleri ve bunlar�n analjezik olarak kullan�lmas�. | |
| ATE406881T1 (de) | Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung | |
| MY117526A (en) | N-(3-benzofuranyl)urea-derivatives | |
| DK0661987T3 (da) | Morphogeninduceret leverregeneration | |
| TW362971B (en) | Pharmaceutical composition and kit for treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M-phase specific anti | |
| ATE413179T1 (de) | Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden | |
| CA2368618A1 (en) | Method of enhancing the efficacy of anti-tumor agents | |
| ATE536178T1 (de) | Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis | |
| TR199701536T1 (xx) | Benzimidazollerin, l�seminin tedavisi i�in bir ila� �retilmesinde kullan�m�. | |
| JPS5767518A (en) | Radiosensitizing agent or agent for increasing effect of radiomimetic substance | |
| Dufour et al. | 5-Fluorouracil versus 5-fluorouracil plus α-interferon as treatment of metastatic colorectal carcinoma. A randomized study | |
| DE69735722D1 (de) | D-methionin zur reduzierung der toxizität von platin-enthaltenden antitumor verbindungen | |
| DE69026387D1 (de) | Reduktion der nichtzielspezifischen retention von immunokonjugaten und ihren metaboliten | |
| ATE22282T1 (de) | Pentacycloundecan derivate, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen. | |
| DK1023314T3 (da) | Galdesyredsalte af metaller med fysiologisk virkning og anvendelsen deraf ved terapi | |
| TR200003449T2 (tr) | Ensülin duyarlılığını ve glükoz metabolizmasını iyileştirmek için D-chiro- inositol içeren farmasötik terkip | |
| DE60203895D1 (de) | Verwendung von n-acetyl-d-glucosamin bei der herstellung eines arzneimittels zur unterdrückung der nebenwirkungen von strahlentherapie und chemotherapie | |
| Cold | Cerebellar dysfunction during high dose cytosine arabinoside therapy in a case of acute myelogenous leukaemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1019036 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |